However, Kaplan–Meier analysis revealed significantly reduced survival rates among early-BC patients with TLR4 expression on PBMCs (identified by using any expression (>0%) or mean expression (>5.2%) as thresholds for positivity) (median DFS: NR vs. NR; p = 0.020 and p = 0.006, respectively, and median OS: NR vs. NR; p = 0.061 and p = 0.028, respectively) (Figure 4A,B). The gene discussed is TLR4; the disease is breast cancer.